BioSpace News Archive

The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.

This opportunity adds the Kent device to Allegan Canada’s Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®, Natrelle®, Revolve®, and the Keller Funnel®.

For a second year, dentists topped the list of health practitioners Americans want to see more often, according to a survey from Delta Dental.

Bayer and Ginkgo Bioworks announced the official name of its joint venture, Joyn Bio.

SRF231 is a fully human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells which prevents them from being engulfed and eliminated by macrophages.

Exclusive two-way licensing deal promises to accelerate growth for both companies

Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.

Study to investigate new therapeutic approach for generalized epilepsy with absence seizures

Atlanta-based Piedmont Healthcare will implement Glytec’s eGlycemic Management System® across all acute care facilities.

Genentech announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ®.